CRS Clinical Research Services Mannheim GmbH
Mannheim, 68167, Germany
NCT Number: NCT04801693
The main objectives of the single rising doses (SRD) trial part are to investigate safety, tolerability and pharmacokinetics (PK) of BI 1819479 in healthy male subjects following administration of single rising doses.
The main objective of the food effect part is to investigate the influence of food on the relative bioavailability of BI 1819479.
Looking for future studies?
Notify Me18 year–50 year
Male
Interventional
Phase 1
Mannheim, 68167, Germany
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
BI 1819479
Placebo
Time frame: Up to Day 36
Single rising doses (SRD) part
Time frame: Up to Day 31
Food effect part
Time frame: Up to Day 31
Food effect part
Time frame: Up to Day 31
SRD part
Time frame: Up to Day 31
SRD part
Time frame: Up to Day 31
Food effect part
Boehringer Ingelheim
Industry
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 1819479 in Healthy Male Subjects (Single-blind, Randomised, Placebo-controlled Parallel Group Design) and Effect of Food on the Relative Bioavailability of BI 1819479 (Open-label, Randomised, Two-way Crossover Design)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07232732
Body Weight, Healthy
Daytona Beach, Florida, United States
View Trial DetailsNCT07781618
Healthy
Bruges, West-Flanders, Belgium
View Trial DetailsNCT04606979
Basal Ganglia Diseases, Brain Diseases
Brussels, Brussels Capital, Belgium
View Trial DetailsNCT05804344
Healthy
New York, United States
View Trial Details